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Suggested guidelines for using systemic 
antimicrobials in bacterial skin infections  
(2): antimicrobial choice, treatment  
regimens and compliance
L. Beco, E. Guaguère, C. Lorente Méndez, C. Noli, T. Nuttall, M. Vroom
Systemic antimicrobials are critically important in veterinary healthcare, and resistance 
is a major concern. Antimicrobial stewardship will be important in maintaining clinical 
efficacy by reducing the development and spread of antimicrobial resistance. Bacterial skin 
infections are one of the most common reasons for using systemic antimicrobials in dogs 
and cats. Appropriate management of these infections is, therefore, crucial in any policy for 
responsible antimicrobial use. The goals of therapy are to confirm that an infection is present, 
identify the causative bacteria, select the most appropriate antimicrobial, ensure that the 
infection is treated correctly, and to identify and manage any underlying conditions. This is 
the second of two articles providing evidence-led guidelines to help practitioners address 
these issues. The first article (VR, January 19, 2013, vol 172, pp 72-78) discussed the use of 
clinical signs, cytology and culture in diagnosis. This second article covers the rationale  
for topical and systemic antimicrobial therapy, including choice of first-, second- and  
third-line drugs, the dose, duration of therapy, compliance and identification of underlying 
predisposing conditions. In addition, there is guidance on cases of therapeutic failure and 
environmental hygiene. These guidelines should help veterinarians avoid the development 
and propagation of antimicrobial-resistant bacterial strains.
Therapy: selecting an appropriate antibiotic
Systemic or topical treatment?
Once a pyoderma has been diagnosed, it is important to consider if the 
infection is deep, severe and/or generalised enough to warrant treat-
ment with systemic antibiotics. Preferred alternatives for mild, surface 
and/or focal infections include topical antimicrobial shampoos and 
sprays, or even topical antibiotics if topical antiseptics do not clear the 
infection. Topical antiseptic treatments can hasten clearing the infec-
tion, or will greatly reduce the need for systemic therapy (Scott and 
others 2001, de Jaham 2003, Murayama and others 2010).
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Systemic antibiotics
If systemic antibiotics are considered the best approach, there are five 
relevant points to take into consideration:
n The vast majority of skin infections are associated with coagulase-
positive staphylococci.
n The skin is the largest organ of the body, and its blood supply is 
comparatively poor.
n The length of treatment will depend on the depth of the infection.
n Most cases of canine pyoderma are secondary to other pathologies, 
which must be addressed to obtain a clinical cure.
n Using topical antiseptic treatment will hasten clearing the infection.
Choice of antibiotic
The vast majority of skin infections in companion animals are associ-
ated with coagulase-positive staphylococci, with Staphylococcus pseud-
intermedius (part of the Staphylococcus intermedius group [SIG]) the most 
common causative agent in canine pyoderma (Devriese and others 
2005, Bannoehr and others 2007).
There have been many studies describing the antibiotic susceptibil-
ity of SIG isolates (eg, Medleau and others 1986, Ihrke 1987, 1996, Piriz 
and others 1996, Pellerin and others 1998, Ganiere and others 2005, 
Jones and others 2007, Norström and others 2009, Yoon and others 
2010, Ghidini and others 2011). These show that the antibiotic sensitiv-
ity of SIG isolates vary. In particular, the number of drug-resistant, mul-
tidrug-resistant (ie, resistant to three or more classes of antimicrobial), 
and meticillin-resistant isolates has increased over time. Regular updates 
on susceptibility patterns to antimicrobials used in veterinary medicine 
are therefore required (Authier and others 2006). In addition, antimi-
crobial susceptibility patterns vary between countries, and clinicians 
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should use data relevant to their location. A recent systematic review 
of systemic antibiotic therapy for canine pyoderma evaluated 17 clinical 
trials (Summers and others 2012). The authors concluded that there was 
good evidence supporting the high efficacy of subcutaneously injected 
cefovecin in superficial pyoderma and for oral clavulanate-amoxicillin in 
deep pyoderma. There was fair evidence for moderate to high efficacy 
of oral clavulanate-amoxicillin, clindamycin, cefadroxil, trimethoprim-
sulfamethoxazole and sulfadimethoxine-ormetoprim in superficial 
pyoderma, and oral pradofloxacin, oral cefadroxil and subcutaneously 
injected cefovecin in deep pyoderma. It is possible to use this efficacy 
data and SIG susceptibility data to estimate the probability of successful 
management of staphylococcal skin infections with different antibiot-
ics, and classify them into first-, second- and third-line antibiotics.
First-line antibiotics
First-line antibiotics include established and well-tolerated narrow- 
and broad-spectrum drugs with antistaphylococcal activity. They 
are no less potent than higher-tier drugs in the correct circumstances, 
and are appropriate for empirical treatment of uncomplicated canine 
 pyoderma. First-line drugs include cefadroxil, cefalexin, clavulanate-
amoxicillin, clindamycin and lincomycin. Cefpodoxime and cefovecin 
can be included as first-line antibiotics where medication may be dif-
ficult, and/or compliance is, or likely to be, poor (Van Vlaenderen and 
others 2011). Long-term injectable or once-daily palatable oral antibi-
otics are useful if there is, or is likely to be, poor adherence to the treat-
ment regimen, problems with communicating the treatment regimen 
to the owner, and/or multiple therapies within a treatment regimen.
Inherent resistance of staphylococci limits the usefulness of tet-
racyclines (Kim and others 2005, Yoon and others 2010), some sul-
fonamides (Papich 1988) and simple penicillins (Abraham and Chain 
1988, Yoon and others 2010). Tetracyclines and sulfonamides, howev-
er, may be useful for meticillin-resistant Staphylococcus aureus or S pseud-
intermedius infections when their use is indicated by in vitro sensitivity 
tests (Morris and others 2006).
Second-line antibiotics
Second-line antibiotics should only be used when there is culture 
evidence that first-line drugs will not be effective. These antibiotics 
are not appropriate for empirical antibiotic treatment (Authier and 
others 2006). Second-line antibiotics include newer broad-spectrum 
drugs important to animal and human health where the development 
of resistance is of greater concern. Second-line antibiotics include 
cefovecin, cefpodoxime, difloxacin, enrofloxacin, marbofloxacin, 
orbifloxacin and pradofloxacin. The recent decline in staphylococcal 
susceptibility to fluoroquinolones is probably due to the common use 
of these drugs (Prescott and others 2002). To limit the emergence of 
resistance, fluoroquinolones should only be used where second-line 
antimicrobials are necessary (Authier and others 2006).
Third-line antibiotics
Third-line antibiotics are very important to animal and human health, 
especially for treatment of multidrug-resistant organisms. Resistance 
towards these drugs is of great concern and/or they have greater poten-
tial for adverse effects. Most of these drugs are not licensed for ani-
mals, and there are few safety and efficacy data. Third-line antibiotics 
must only be used when there is culture evidence of sensitivity, no 
first- or second-line antibiotics are effective, and topical antimicrobial 
therapy is not feasible or effective (Authier and others 2006). Third-
line antibiotics include aminoglycosides, azithromycin, ceftazidime, 
chloramphenicol, clarithromycin, florphenicol, imipenem, phospho-
mycin, piperacillin, rifampin, tiamphenicol and ticarcillin.
The development of resistant bacteria in human health is a big 
concern. In their ethical role of healthcare professionals, veterinarians 
should never use drugs deemed critically important to human health 
(eg, vancomycin, teicoplanin, linezolid, etc) in animals. Some coun-
tries, moreover, expressly prohibit the use of human antibiotics not 
licensed for animals (eg, azithromycin, ceftazidime, clarithromycin, 
imipenem, phosphomycin, piperacillin, rifampicin, ticarcillin and oth-
ers), so those antibiotics should preferably be avoided, even if there is 
evidence of sensitivity. Clinicians are responsible for ensuring that it is 
legal to use non-licensed drugs in their countries.
Escalation and de-escalation of treatment
Ideally, treatment should not be started until the results of bacterial 
cultures and antimicrobial sensitivity tests are available. If immediate 
treatment is necessary, the selection of an appropriate drug should be 
based on clinical signs and cytology, bearing in mind the most likely 
organisms and their likely antimicrobial sensitivity patterns in each 
case. When culture results become available, clinicians should be pre-
pared to escalate treatment by selecting a higher-tier drug, or de-esca-
late treatment to a lower-tier drug, as indicated.
Antibiotic dose, duration, adverse effects 
and compliance issues
Antibiotic dose
The skin is the largest organ of the body, and its blood supply is com-
paratively poor (Scott and others 2001). Antibiotics should, therefore, 
be used at the upper end of their dose range in pyoderma. Animals 
should always be weighed to allow accurate dosing. If necessary, 
slightly overdose – never underdose.
The following are effective doses for the most common antibiot-
ics used in canine pyoderma:
n Clavulanate-amoxicillin: 12.5 to 25 mg/kg every 12 hours orally 
(Lloyd and others 1997).
n Cefalexin: 22 to 30 mg/kg every 12 hours, or 30 to 40 mg/kg every 
24 hours orally (Toma and others 2008).
n Cefadroxil: 22 to 30 mg/kg every 12 hours orally (Angarano and 
MacDonald 1989, Frank and Kunkle 1993), or 30 to 40 mg/kg every 
24 hours orally (Noli and Scarampella 1999).
n Lincomycin: 22 mg/kg every 12 hours orally (Harvey and  others 
1993).
n Clindamycin: 11 mg/kg every 12 to 24 hours orally (Harvey and 
others 1993, Saridomichelakis and others 2011).
n Cefovecin: 8 mg/kg every 14 days subcutaneously (Stegemann and 
others 2007, Six and others 2008).
n Cefpodoxime: 5 to 10 mg/kg every 24 hours orally (Brown and 
others 2007, Papich and others 2010, Kumar and others 2011).
n Enrofloxacin: 5 to 20 mg/kg every 24 hours orally (DeManuelle 
and others 1998, Frazier and others 2000, Bidgood and Papich 2005, 
Boothe and others 2006).
n Marbofloxacin: 2.5 to 5 mg/kg every 24 hours orally (Schneider and 
others 1996, Carlotti and others 1999, Frazier and  others 2000, Paradis 
and others 2001, Horspool and others 2004, Boothe and others 2006).
n Difloxacin: 5 mg/kg every 24 hours orally (Boothe and others 2006).
n Orbifloxacin: 2.5 to 7.5 mg/kg every 24 hours orally (Boothe and 
others 2006, Scott and others 2006).
n Pradofloxacin: 3 mg/kg every 24 hours orally (Mueller and Stephan 
2007, Restrepo and others 2010).
n Azithromycin: 10 mg/kg every 24 hours orally (Girard and  others 
1987, Shepard and Falkner 1990).
n Chloramphenicol: 50 mg/kg every eight hours orally.
n Rifampin: 5 to 10 mg/kg every 12 to 24 hours orally.
n Tobramycin: 9 to 14 mg/kg every 24 hours subcutaneously.
n Netilmicin: 9 to 14 mg/kg every 24 hours subcutaneously.
n Amikacin: 15 to 30 mg/kg every 24 hours subcutaneously.
n Gentamicin: 9 to 14 mg/kg every 24 hours subcutaneously.
Duration
The duration of treatment will depend on the depth of the infection. 
Superficial pyodermas typically need two to three weeks of treatment. 
Deep pyodermas can be greatly improved after two weeks, but full reso-
lution often takes four to six weeks or longer (Carlotti and Ovaert 1988, 
Angarano and MacDonald 1989, Guaguère and Marc 1989, Paradis and 
others 1990, Scott and others 1994, 2006, Carlotti and others 1995).
Treatment has to be continued until the infection is visually and pal-
pably cured, and cytology is normal. It is conventional to continue treat-
ment for another seven days in the case of superficial infections, and 
14 days if there was deep infection (Scott and others 2001), although 
the evidence for this is largely anecdotal, and overly long treatment regi-
mens may increase selection pressure for resistance among commensal 
bacteria. Treated cases should be checked every one to two weeks. If 
there is any doubt that complete resolution has not occurred, treatment 
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should be continued, checking cytology and/or culture to  confirm that 
remission is progressing. It is important to note that the clinical signs 
associated with an underlying disease may still be present and must be 
differentiated from the clinical signs of the pyoderma.
Owner compliance
Poor compliance or adherence to treatment is likely to compromise effi-
cacy and encourage resistance. Compliance problems include underdos-
ing, missed doses and stopping treatment early (Barter and others 1996, 
Grave and Tanem 1999), and compliance declines with twice daily or 
more frequent dosing and treatment regimens with more than one 
drug. Furthermore, owners may find it difficult or dangerous to admin-
ister drugs to some animals. Thus, discussing potential problems openly 
and honestly with owners helps to select the most appropriate drug and 
dosing regimen. Compliance can be improved by:
n Using long-duration injectable drugs.
n Using once-daily drugs.
n Using palatable drugs.
n Using drugs that the owner is able to administer safely.
n Convincing the owner of the importance of correct treatment.
n Giving written instructions.
n Using precise terminology – for example, ‘every 12 hours’ instead 
of ‘twice daily’.
n Good follow-up and communication.
n Minimising the number of different drugs or treatments.
Adverse effects
Owners should be warned about common and mild adverse effects, 
such as transient gastrointestinal tract upsets, to avoid them premature-
ly ceasing treatment. Adverse effects arise from effects on non-target 
bacteria, pharmacological activity (usually predictable and dose-related) 
or immune-mediated drug reactions (usually unpredictable and not 
dose-related). Adverse effects can be age-, breed- and species-associated. 
Common adverse effects of antibiotics include, but are not limited to:
n Gastrointestinal tract upsets – vomiting and diarrhoea may be asso-
ciated with broad-spectrum antibiotics. This is usually mild and of 
short duration in dogs and cats, but may be more severe in hindgut-
fermenting species (eg, rabbits, rodents, horses, etc).
n Fluoroquinolones can cause neurological problems (especially 
enrofloxacin in cats and in dogs with a history of seizures) (Ihrke and 
others 1999), and cartilage abnormalities in skeletally immature dogs 
(Gough and others 1992).
n Sulfonamides can be metabolised into immunologically reactive 
derivatives that cause skin reactions, polyarthritis, anaemia, thrombo-
cytopenia and glomerulonephropathy, especially in dobermans (Noli 
and others 1995, Trepanier 1999). Keratoconjunctivitis sicca (Berger 
and others 1995) and hypothyroidism (Hall and others 1993) can also 
be seen, particularly with long-term treatment.
n Penicillins and cefalosporins occasionally trigger allergic and 
immune-mediated drug reactions (Torres and Blanca 2010). Cross-
reaction between penicillins and cefalosporins occurs in 1 to 10 per 
cent of human patients (Adkinson 1998).
n Cefalosporins can induce positive Coomb’s tests, but haemolytic 
anaemia is rare (Johnson and others 2007).
n Cefalosporins can induce renal tubular damage, but clinical toxicity 
is very rare (Barza 1978).
n Chloramphenicol can induce dose- and time-dependent bone mar-
row suppression (Holt and others 1993), although irreversible aplas-
tic anaemia is not generally recognised in animals.
n Aminoglycosides may cause renal toxicity (Martínez-Salgado 
and others 2007), and renal function should be checked before and 
during treatment (Noli and Morris 2011). For this reason, systemic 
aminoglycoside antibiotics should only be considered when there 
is evidence from bacterial culture and sensitivity testing that other 
antimicrobials would not be appropriate, and when topical antimi-
crobial or antibiotic therapy is not appropriate (eg, in deep pyoder-
ma) or has not been effective.
n Tetracyclines may cause hepatotoxicity, photosensitivity, discol-
oured teeth in young animals and teratogenicity.
n Rifampin may cause hepatotoxicity, so hepatic function should be 
checked before and during treatment.
The potential for drug interactions and/or dose adjustments should 
be considered in animals on multiple drugs, and/or with renal or hepatic 
impairment. Reduced metabolism and/or excretion and extended half-
life can cause cumulative dosing and increase the potential for adverse 
effects. It is therefore advisable to use drugs with an alternative route of 
excretion in animals with impaired renal and/or hepatic function, or to 
decrease the dosing interval and/or the dose. However, this may compro-
mise efficacy if adequate tissue levels are not achieved and maintained.
Identification of the underlying cause
The vast majority of skin infections are secondary to a primary condi-
tion, such as a hypersensitivity, ectoparasitic infestation, endocrinopa-
thy or keratinisation defects and so on. Successful long-term manage-
ment requires that these are addressed. It is therefore important that 
the history and clinical signs are evaluated for clues to the underlying 
condition. These should then be investigated and managed as appro-
priate. It is beyond the scope of this article to discuss potential primary 
problems, and clinicians should consult other texts where necessary.
Treatment failures and recurrence
Poor response to treatment
In cases of poor response to treatment, a variety of reasons should be 
carefully considered:
n Is there a bacterial skin infection? Carefully re-evaluate the clinical 
signs, cytology and bacterial culture.
n Are resistant organisms present? Perform or repeat bacterial  culture 
and antibiotic sensitivity.
n Was the antibiotic given correctly? Was the owner compliant? 
Improve communication with the owner.
n Were the dose and the duration correct? Re-evaluate the treatment 
regimen.
n Was there concurrent inappropriate use of immunosuppressive 
drugs, especially systemic glucocorticoids?
n Poor distribution to the target tissue: deep pyodermas often feature 
extensive necrosis, scarring and debris that may limit penetration and 
activity of some antibiotics. Clindamycin, cefovecin and fluoroqui-
nolones penetrate well to sites of skin infection and inflammation and 
could be used in these cases.
Recurrent pyoderma
In recurrent pyoderma, it is important to evaluate the time between drug 
withdrawal and relapse of the skin infection. If the pyoderma relapses 
after a few days, then the antibiotic course was too short. A longer course, 
following bacterial culture and sensitivity testing to check that the drug 
will still be effective, should be administered. If the pyoderma relapses 
weeks or months after antibiotic withdrawal, then there probably is an 
undiagnosed or uncontrolled underlying cause. In order to decrease the 
number and frequency of pyoderma relapses, topical antimicrobial sham-
poos or rinses can be used until the underlying cause is controlled.
A small number of cases, however, will suffer relapsing pyoderma 
if an underlying cause cannot be found (primary pyoderma) or cannot 
be controlled. Immunostimulants, such as Staphphage Lysate (DeBoer 
and others 1990) or autogenous bacterial vaccines (Curtis and others 
2006) can be used in these cases. Topical antibiotics can be suitable 
for focal lesions, and may be useful to treat mucosal reservoir sites 
(Saijonmaa-Koulumies and others 1998). Pulse therapy with  systemic 
antibiotics is not recommended for managing idiopathic recurrent 
pyoderma, as long-term systemic antibiotic treatment is a risk factor 
for the acquisition of antibiotic-resistant organisms. However, as a last 
resort, full-dose bactericidal antibiotics, such as clavulanate-amoxicil-
lin or cefalexin may be given on two to three consecutive days each 
week (‘weekend therapy’) (Carlotti and others 2004). Long-duration 
injectable antibiotics are not suitable for pulse dosing.
Hygiene measures
Antibiotic resistance is an emerging problem in veterinary and human 
medical care, and constitutes a threat to animal welfare and public 
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health. Good hygiene routines are necessary to prevent and control 
infections and minimise zoonotic risk. Suggested measures to improve 
hygiene standards in veterinary healthcare premises are based on 
minimising the risk of contamination of clothes, skin (especially the 
hands), instruments, clipper blades and the environment.
Work clothes should be changed at least daily (or more often if con-
taminated), and should not be used outside the clinical setting. Wearing 
short sleeves and restricting jewellery to simple wristwatches and wed-
ding rings are important for proper hand hygiene. Alcohol-based (pro-
panol 60 per cent w/w, ethanol 70 to 90 per cent w/w or isopropanol 
60 to 80 per cent w/w) hand disinfection is effective in reducing tran-
sient microbial flora (Rotter and others 1998, WHO 2009, Kampf and 
Loffler 2010), but hand washing with warm water and a detergent is 
necessary if the hands are visibly soiled. To minimise the drying effect 
of alcohol, humectants and/or emollients can be added (Kampf and 
others 2005). Chlorhexidine should be avoided for hand disinfection 
of personnel, as chlorhexidine contact allergy can occur (Liippo and oth-
ers 2011). Gloves do not substitute for hand hygiene. Hands should be 
disinfected before and after contact with a patient, before gloves are put 
on (as the integrity of gloves can be breached during the procedure), and 
after the use of gloves. After handling contaminated material, personnel 
should dispose of gloves and disinfect hands before touching a clean 
area. Unnecessarily frequent or prolonged use of gloves should be avoid-
ed as this can lead to development of hand eczema (Cleenewerck 2010).
Frequently touched surface areas in the environment, such as door 
handles, lamp handles and buttons, and microscope knobs need extra 
attention, and should be cleaned daily with non-corrosive disinfect-
ants. As disinfectants can be partly inactivated when in contact with 
organic debris, mechanical cleaning (for example, with alcohol in 
combination with a surfactant/detergent) is important before disinfec-
tion. Spraying or pouring disinfectants on top of a dirty surface will 
not suffice in many instances. Non-disposable instruments should be 
cleaned and sterilised. Ear cones and clipper blades should ideally be 
autoclaved after use in veterinary practice. Computer keyboards have 
also been shown to be contaminated frequently with Pseudomonas and 
Enterococcus species, and should be disinfected regularly (Fraser and 
Girling 2009). Washable keyboards should be used in clinical areas.
Patients with known or suspected contagious diseases and infec-
tions with multiresistant bacteria should be booked last in a day if pos-
sible, and ideally evaluated in a special consulting room. Extra hygiene 
measures should be undertaken when handling the patient. After the 
consult, the room should be cleaned before the next patient is allowed 
in. At this point, it is unknown for how long a dog that had an infection 
with a multiresistant Staphylococcus species can be an asymptomatic car-
rier of the bacteria. Owners of such patients can be asked to shampoo 
the dog with an antibacterial shampoo before coming into the clinic. 
Those dogs should not spend time in the waiting room. If possible, 
the dog should wait in the car, or outside with the owner, and then go 
straight into the consult room (FECAVA 2010, BSAVA 2011).
Clinic hygiene measures will only be successful if the board of the 
clinic is supportive, and all members of the staff stick to the protocol. 
Correctly implemented hygiene routines are an important contribu-
tion to patient and staff welfare, and are mandatory for high-quality 
veterinary healthcare.
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